Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a report on Wednesday, February 12th.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $0.14 on Tuesday. The firm has a market capitalization of $9.25 million, a price-to-earnings ratio of -0.05 and a beta of 0.88. Aptose Biosciences has a one year low of $0.13 and a one year high of $1.94. The company’s 50 day moving average price is $0.20 and its 200 day moving average price is $0.30.

Aptose Biosciences’s stock is set to reverse split on the morning of Wednesday, February 26th. The 1-30 reverse split was announced on Tuesday, February 18th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, February 25th.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 703,384 shares of the biotechnology company’s stock after acquiring an additional 301,634 shares during the period. Sigma Planning Corp owned about 1.17% of Aptose Biosciences worth $158,000 as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.